Replies to post #1852 on Enanta Pharmaceuticals Inc (ENTA)

[DaveAu]

ENTA isn’t getting a bounce from this announcement—and it doesn’t deserve one insofar as this is a low-key program that’s unlikely to bear fruit in a manner that’s commercially material.

I assume it must be fairly cheap for them to muck around with this given the similarities to existing programs. Why make the announcement though if it's not material? They've never been overly promotional before.

[biocqr]

Baird upgrades 'defensive' Enanta, sees 'real COVID-19 potential'

Baird analyst Brian Skorney upgraded Enanta to Outperform from Neutral with a $60 price target. He sees the company having a defensive cash and royalty position and also views its core competencies in virology and respiratory disease as "among the best to tackle COVID-19," Skorney tells investors. Enanta's two-pronged development approach should give it the potential for a viable COVID-19 candidate to come from it pipeline in either the near or long term, Skorney added.